-
Phase III Epacadostat + Keytruda Trial Failure: How Will it Impact the Oncology Landscape?
Forecasting the likelihood of success of late-phase clinical trials in oncology is complex. Positive efficacy signals observed in early-phase trials are frequently not reproduced in more rigorous,...
-
Biosimilars Insights Infographic
Global Biosimilars Pathways and Clinical Development Activity Since the introduction of the first biosimilar guidelines in 2005, the biosimilars field has continued to evolve. Over fifty biosimilars...
-
The Art of the Oncology Deal
The number of deals in the pharmaceutical space has the tendency to fluctuate, but in recent years there has been a proportional increase in the amount of strategic partnerships, acquisitions, and...
-
The Politics of US Healthcare: Implications of MACRA on Physicians, Bundled Payments, Medicare, & Tech
This live session took place on Thursday, March 8th 2018. With new Health and Human Services Secretary Alex Azar now at the helm, provider Medicare reimbursement changes are looming under the Medicare...
-
Mapping the Clinical Path in Rheumatoid Arthritis With Real World Data
Real World Data has the potential to boost brand performance, fine-tune commercial strategy, tease out subtle market nuances, and unlock hidden opportunities. The below infographic utilizes US...
-
Global Market Access: Key Events in 2017
Where is the marketing authorization process becoming more favorable to industry? Where does industry need to monitor HTA development? How are countries seeking to rein in drug spending? The global...
-
Regenerative Medicine 2017
Both gene and cell therapies do not yet have a foothold in the market but the potential for a market explosion is not only possible, but well on its way to becoming inevitable. The following...
-
Biosimilar Substitution by State
Some states don’t have substitution laws--find out which ones. Pharma and payers often disagree over how U.S. states should address substitutions of low-cost versions of biologic drugs. Many...
-
DRG Epidemiology’s Global Lung Cancer Forecast, 2017-2027
This live session took place on Wednesday, December 6th, 2017. Wei Wei Zhang presented DRG’s epidemiological forecast of all those living with lung cancer in 2017 and who will develop lung cancer by...
-
Pharma and Value-Based Contracting: Gauging Market-Readiness for Outcomes-Based Arrangements
This live session took place on Tuesday, November 28th, 2017. Value-based contracts that align drug prices with quality and patient outcomes are gradually gaining traction as the U.S. healthcare...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
